Building momentum

Why investors flocked to cell therapy company Avrobio’s $60M series B round

Avrobio Inc. parlayed positive clinical data and an aggressive in-licensing strategy into a $60 million series B round that will fund early clinical development of three long-acting lysosomal storage disease candidates.

Cormorant Asset Management and Surveyor Capital led the

Read the full 387 word article

User Sign In